Rucaparib phosphate, PARP inhibitor (TBI3321)

Description

Product Details

Formal Name: 8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-one

Alternate Names: AG-14699; PF01367338

Molecular Formula: C₁₉H₁₈FN₃O ∙ H₃PO₄

Formula Weight: 421.36

CAS Number: 459868-92-9

Purity: >98%

Formulation: powder

Solubility: Soluble in DMSO (up to 25 mg/ml)

Storage: -20°C

Stability: ≥ 1 year.

 

Applications

PARP inhibitor

 

Functions

Rucaparib is a potent (Ki<5 nM) PARP1 inhibitor. Cytotoxic to human cancer cells or xenograft tumors with mutated or epigenetically silenced BRCA1/2. Demonstrates antiproliferative effects in 26 out of 39 ovarian cancer cell lines. Synergizes with other anticancer agents such as topotecan, carboplatin, doxorubicin, paclitaxel and temozolamide. Ameliorates the cardiotoxicity of doxorubicin. Recently approved for human use by the FDA.

 

Application Procedures

First dissolved in DMSO (up to 25 mg/ml), then diluted to aqueous buffer. Solutions in DMSO may be stored at -20° for up to 3 months.

Additional information

SIZE (mg)	25 MG, 5 MG

Datasheet:

TBI3321_Rucaparib phosphate

MSDS:

TBI3321_Rucaparib phosphate_MSDS_2024